# Characterization of FE 999049 Tolerability in United States (US) Women Undergoing Controlled Ovarian Stimulation, A RITA Trial Analysis

V.L. SCHNELL[1], A. BRENNER[2], J. KAWULA[2], S. GROVER[2], E. FOSTER[2], O. ELCI[2], P. MANN[2], P. HEISER[2], on behalf of RITA trial investigators

1 Shady Grove Fertility, Houston, TX

2 Ferring Pharmaceuticals, Inc., Parsippany, NJ

ASRM 2025
Global Collaboration to Advance Reproductive Health
San Antonio, Texas
October 25-29, 2025

## PURPOSE & OBJECTIVES

- FE 999049 is a human cell line-derived recombinant follicle stimulating hormone (rFSH; **follitropin delta**) used in ovarian stimulation[1-4]
- The efficacy and safety of follitropin delta were assessed in the RITA trials[5]
- Follitropin delta is administered subcutaneously using a **pre-filled injection pen**
- **Objective:** To assess the frequency and intensity of injection site reactions associated with follitropin delta administration in the RITA trials

## MATERIALS & METHODS

- RITA-1 and RITA-2 were randomized, double-blind, placebo-controlled, parallel-groups trials conducted in 24 US fertility clinics from 2018 to 2020
- Patients were randomized 10:1 to follitropin delta or placebo, provided in a pre-filled pen for subcutaneous injection (**Figure**)
  - **RITA-1:** 18-34 years of age, daily starting dose of 12 µg follitropin delta (N=525) or placebo (N=53)
  - **RITA-2:** 35-42 years of age, daily starting dose of 15 µg follitropin delta (N=533) or placebo (N=54)
  - Dose adjustments in 3 µg increments, based on ovarian response, from day 5 of stimulation onward
  - Preimplantation genetic testing was not permitted
- Local tolerability was assessed by the patient immediately, 30 minutes, and 24 hours after injection
- **Injection site reactions** were classified as redness, pain, itching, swelling, or bruising with intensity rated as none, mild, moderate, or severe

## CONCLUSIONS

The RITA-1 and RITA-2 trials demonstrated high local tolerability of follitropin delta subcutaneous injection via a pre-filled pen, with incidence and severity of injection site reactions similar to those of placebo.

## RESULTS

**Patient-reported injection site reactions and severity in the RITA trials**

| | Follitropin delta | Placebo |
|---|---|---|
| | Event (%) | Event (%) |
| ANY SYMPTOM | | |
| Mild | 5209 (4.1) | 635 (4.8) |
| Moderate | 137 (0.1) | 12 (0.1) |
| Severe | 12 (<0.1) | 1 (<0.1) |
| REDNESS | | |
| Mild | 2348 (9.1) | 265 (9.9) |
| Moderate | 24 (0.1) | 1 (<0.1) |
| Severe | 4 (<0.1) | 0 (0) |
| PAIN | | |
| Mild | 1022 (4.0) | 170 (6.4) |
| Moderate | 21 (0.1) | 3 (0.1) |
| Severe | 0 (0) | 0 (0) |
| ITCHING | | |
| Mild | 199 (0.8) | 24 (0.9) |
| Moderate | 5 (<0.1) | 0 (0) |
| Severe | 0 (0) | 0 (0) |
| SWELLING | | |
| Mild | 211 (0.8) | 22 (0.8) |
| Moderate | 8 (<0.1) | 0 (0) |
| Severe | 0 (0) | 0 (0) |
| BRUISING | | |
| Mild | 1429 (5.6) | 154 (5.8) |
| Moderate | 79 (0.3) | 8 (0.3) |
| Severe | 8 (0.1) | 1 (<0.1) |

**Ovarian Stimulation with Follitropin Delta in the RITA Trials**




**Primary Efficacy Endpoint**

Cumulative ongoing pregnancy rate after 12 months:
RITA-1: 64.0%
RITA-2: 43.9%

**Tolerability (Table)**

Injection site reactions across all timepoints in both RITA trials:

Follitropin delta: 4.2% | Placebo: 4.9%

In both groups across RITA-1 and RITA-2:
- Redness was the most frequently reported injection site reaction
- Most injection site reactions were reported as mild
- 0.1% of injection site reactions reported as moderate/severe

## KEY TAKEAWAYS

- Follitropin delta was well-tolerated in the randomized, placebo-controlled RITA trials
- Patient-reported injection site reactions were similar for follitropin delta and placebo, administered subcutaneously using a pre-filled pen
- Follitropin delta provides an effective and well-tolerated treatment option for ovarian stimulation

## ACKNOWLEDGEMENTS

The authors thank the patients, the investigators at the participating sites, and the clinical trial teams at Ferring Pharmaceuticals, especially Joan-Carles Arce MD, PhD, and Lisbeth Helmgaard for contributions to trial design, and Jennifer Kawula, Alyssa Saputo, and Heidi Aasted for leading the operational execution.

## CONTACT INFORMATION

Vicki L. Schnell, MD
vicki.schnell@sgfertility.com

## REFERENCES

**1.** Nyboe Andersen A, et al. Fertil Steril. 2017;107:387-396.e4. **2.** Qiao J, et al. Hum Reprod. 2021;36:2452–62. **3.** Ishihara O, Arce JC. Reprod Biomed Online. 2021;42:909–18. **4.** Nelson SM, et al. Fertil Steril. 2024;122:445–54. **5.** Scheiber MD, et al; RITA-1 and RITA-2 trial group. Fertil Steril. 2025:S0015-0282(25)00605-3.